Mexico · Spanish · COFEPRIS
COFEPRIS translation, built for first-cycle acceptance.
A focused entry point into what COFEPRIS expects from Spanish clinical trial and registration documentation — and how an Amavita pilot delivers it without oficios that stall your calendar.
What this covers
COFEPRIS in three moving parts.
What must be in Spanish
Protocol, ICF, IB, SUSAR narratives, lab manuals, and IFUs — with Mexican regulatory terminology, not neutral Latin American Spanish.
Jump to section →Certification rules
Perito traductor for legal instruments, MD-signed technical review for clinical documents, and consistent translator attestation across the dossier.
Jump to section →Where submissions stall
Inconsistent drug nomenclature, missing appendix translations, and formatting that breaks source pagination trigger oficios and delay authorization.
Jump to section →Ready to scope your Mexico pilot?
Start the pilot form and get a timeline in 2 business days.
Frequently asked
COFEPRIS translation, quick answers.
What is the COFEPRIS translation requirement for a clinical trial protocol?
COFEPRIS requires the protocol, informed consent form, investigator's brochure, and safety narratives in Spanish, with terminology aligned to Mexican regulatory practice and certified by a perito traductor when the source document is legally binding.
Do I need a perito traductor for COFEPRIS submissions?
For legal instruments (powers of attorney, apostilled documents) and formal certifications, yes. For technical documents like protocols and investigator brochures, translations must be prepared by qualified medical translators and signed off by a certified professional.
How does the Amavita pilot cover COFEPRIS submissions?
A pilot scopes one protocol or dossier for Mexico, delivers an MD-reviewed Spanish package (protocol, ICF, IB summary), and includes a pre-submission QC checklist against current COFEPRIS expectations.
How COFEPRIS compares to the rest of the world.
COFEPRIS does not set its rules in isolation. Our primary-source review of preclinical translation requirements across nine LATAM regulators places Mexico on the same three-tier map used above, so you can see where COFEPRIS is stricter — and where it is more permissive — than its neighbours.
Outside the region the picture changes again. The companion study of preclinical translation rules at eight non-LATAM regulators, from FDA and EMA to PMDA, NMPA, MHRA, Health Canada, TGA and Swissmedic found no primary instrument requiring visual replication of a Module 4 study report, which is why the sworn-translation ceiling described on this page is a LATAM-native construct.
If you are budgeting a multi-country programme, read the three-tier framework for COFEPRIS preclinical translation in the LATAM regulator study before deciding what to translate for Mexico.
Next step
Scope a COFEPRIS pilot this quarter.
Share your Mexico protocol or registration dossier. Our team will reach out within 2 business days with a scoped pilot proposal and timeline.